AR and breast cancer: Strikingly, the metastases in mCRPC patients who have failed long-term Enza treatment [82] manifest clear-cut lineage plasticity exhibiting much reduced luminal cell (AR signaling) signature but increased BC, SC, MES and neural gene signatures (Figure 3; right).